Healthcare Services

Female Infertility Market Developments Influencing Industry Expansion Through 2030

May 28, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Growth In Market Size Of The Female Infertility Market During 2026–2030?

The female infertility market has experienced consistent expansion in recent years. It is projected to grow from $1.86 billion in 2025 to $1.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.1%. This historical growth can be attributed to factors like delayed childbearing trends, increased awareness surrounding infertility, the availability of fertility medications, the expansion of reproductive health clinics, and enhanced diagnostic imaging capabilities.

The female infertility market is projected to experience consistent expansion over the upcoming period. This market is anticipated to reach a valuation of $2.26 billion by 2030, driven by a compound annual growth rate (CAGR) of 3.8%. Factors contributing to this growth during the projected timeframe include innovations in fertility drug compounds, the rise of tailored fertility solutions, greater uptake of AI-driven fertility monitoring, the spread of fertility tourism, and increased capital allocation towards reproductive health. Key trends foreseen for the forecast period encompass a surge in demand for assisted reproductive technologies, heightened attention on therapies targeting hormones and ovulation, broader deployment of sophisticated diagnostic methods, an increase in fertility clinics and their offerings, and the incorporation of digital platforms into fertility management.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20787&type=smp

What Influential Factors Are Boosting The Female Infertility Market Demand?

The rising incidence of infertility is projected to boost the expansion of the female infertility market in the future. It is defined as the inability to achieve conception following 12 months of consistent, unprotected sexual activity. The surge in infertility stems from various factors, including postponing childbirth, shifts in lifestyle, exposure to environmental toxins, growing rates of obesity, and elevated stress levels. Treatment for female infertility becomes necessary to manage and resolve fundamental medical, hormonal, or structural problems that hinder fertility, consequently improving the likelihood of conception and averting irreversible infertility. For example, data from April 2023 by the World Health Organization, an intergovernmental body situated in Switzerland, reveals that around 17.5% of adults worldwide, equating to roughly 1 in 6 people, experience infertility. Consequently, the growing occurrence of infertility propels the development of the female infertility market.

Which Segment Groups Define The Female Infertility Market Landscape?

The female infertility market covered in this report is segmented –

1) By Treatment: Clomiphene Citrate, Gonadotropins, Metformin, Letrozole, Bromocriptine

2) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations

3) By End-User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Clomiphene Citrate: Oral Clomiphene Citrate, Injectable Clomiphene Citrate

2) By Gonadotropins: Recombinant Gonadotropins, Urinary Gonadotropins, Human Chorionic Gonadotropin (hCG)

3) By Metformin: Immediate-Release Metformin, Extended-Release Metformin

4) By Letrozole: Oral Letrozole Tablets, Injectable Letrozole

5) By Bromocriptine: Oral Bromocriptine Tablets, Intranasal Bromocriptine

What Trends Are Influencing The Female Infertility Market Outlook?

Leading corporations active within the female infertility market are directing their efforts towards creating advanced solutions, including non-invasive diagnostic tests, to secure a competitive advantage in the sector. A non-invasive diagnostic test is defined as a medical examination capable of identifying ailments or illnesses without necessitating surgical intervention or bodily incision. As an illustration, in August 2024, Heranova Lifesciences, a US-based biotechnology company, initiated an early access program for HerResolve, which is a non-invasive diagnostic tool for endometriosis. Endometriosis impacts approximately 200 million women globally, manifesting symptoms such as infertility, discomfort, and hemorrhage. For numerous women, achieving a precise diagnosis typically requires an average of 7-10 years from the initial appearance of symptoms. This extended period is primarily attributed to the diverse ways symptoms present and the invasive characteristic of exploratory laparoscopic surgery, which stands as the most dependable diagnostic approach currently available. HerResolve offers the potential to decrease this diagnostic waiting period from years to merely months, consequently fostering superior outcomes for both patients and healthcare providers, as it is specifically designed to substantially accelerate this timeline, enhancing overall patient care and results.

Who Are The Firms Contributing To The Female Infertility Market Ecosystem?

Major companies operating in the female infertility market are Pfizer Inc, Merck And Co Inc, Mayo Clinic, Teva Pharmaceutical Industries Ltd, Organon Theramex, Juniper Reproductive Health Ltd, Ferring Pharmaceuticals, Mankind Pharma, ARMC IVF, Zydus Cadila Healthcare, IBSA Institut Biochimique, Oxolife, Ava AG, Merck KGaA, Gedeon Richter Plc, Novartis AG, AbbVie Inc, Ipsen, Theramex, Vitrolife AB, Conceivable Life Sciences, AIVF

Access The Complete Female Infertility Market Report:

https://www.thebusinessresearchcompany.com/report/female-infertility-global-market-report

Which Region Commands The Largest Share Of The Female Infertility Market?

Europe was the largest region in the female infertility market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the female infertility market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Female Infertility Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=20787&type=smp

Browse Through More Reports Similar to the Global Female Infertility Market 2026, By The Business Research Company

Male Fertility Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/male-fertility-global-market-report

Fertility Drugs Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/fertility-drugs-global-market-report

Fertility Treatments Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/fertility-treatments-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795